- New system allows co-registration of angiography with
intravascular imaging (IVUS)
SAN DIEGO, April 25, 2014 /PRNewswire/ -- Volcano
Corporation (NASDAQ: VOLC), a leading developer and manufacturer of
precision guided therapy tools designed to enhance the diagnosis
and treatment of coronary and peripheral vascular disease, today
announced the commencement of its limited market release of its FDA
cleared and CE marked technology SyncVision™, with cases being
performed in the U.S. and Europe.
SyncVision™ is currently installed in multiple limited market
release sites throughout U.S. and Europe.
Volcano's SyncVision™ Technology System is an on-line image
processing workstation for coronary catheterizations that allows
the physician to navigate simultaneously on an angiogram and on an
IVUS image in a single correlated view using co-registration of the
Eagle Eye® Platinum catheter with x-ray angiography.
SyncVision™ is designed to bring the detailed vessel, lumen and
wall structure from angiography and the spatial localization of
Volcano's intravascular ultrasound images within the coronary tree
together in a co-registered view to facilitate more informed
treatment decisions and more efficient, enhanced workflow
performance.
"SyncVision™ is an important advancement in clinical IVUS
imaging. It allows us to correlate significant IVUS findings with
the corresponding spots on the angiogram. This addresses a
challenging aspect of current practice in that it can be difficult
to identify the precise spot needing treatment in translating the
IVUS findings to the angiogram," commented Steven Goldberg, M.D., Director, Cardiac
Catheterization Laboratory and Clinical Associate Professor of
Medicine at University of Washington
Medical Center. "It also allows for simple and precise length
measurements to help inform stent selection. Co-registration of
different imaging modalities is currently the wave in
interventional cardiology, and I think this is one of the most
useful and user friendly co-registration formats I have seen. I
believe that this truly represents the next generation in IVUS
imaging."
"The co-registration with angiography makes of IVUS an entirely
new instrument. As a regular IVUS user, I was impressed to see how
it helps in making decisions based on intracoronary imaging,"
commented Javier Escaned, M.D., Consultant Interventional
Cardiologist, Hospital Clinico San Carlos. "In addition, the
angiographic tools incorporated in SyncVision™ are extremely
helpful during coronary interventions. Image stabilization and
digital enhancement based not only on cine but also on images under
fluoroscopy is a great complement of IVUS in performing accurate
stent optimization without geometric mismatch. My impression is
that with this system we move into an entirely new era of
integration of IVUS and angiography in clinical practice."

"We are looking forward to sharing the SyncVision™ technology
with a global audience next month at the EuroPCR meeting in
Paris," said Joe Burnett, Executive Vice President. "We will
showcase the technology with working systems at our booth and in
the training village, as well as with expert panel discussions and
live case presentations."
"We are thrilled about the benefits and precision that the use
of SyncVision™ enables in concert with our Eagle Eye Platinum
Catheter and the Angio +™ applications. SyncVision™ will change the
game in that it empowers easier and better interpretations of both
IVUS and angio technologies that are designed to encourage quicker
and confident decisions," said Scott
Huennekens, President and Chief Executive Officer.
"SyncVision™ Technology System demonstrates innovation in design
and a commitment to our continued investments in Volcano solutions
for our customers. This system further bolsters our portfolio of
recent innovative releases with the iFR® modality, CORE™
Precision Guided System, and CORE™ Control Pad—all of which work to
help improve patient outcomes and customer productivity."
SyncVision™ is expected to be in full market release later in
2014. Additional product information is available at
www.volcanocorp.com.
About Volcano Corporation
Volcano Corporation is revolutionizing the medical device
industry with a broad suite of technologies that make imaging and
therapy simpler, more informative and less invasive. Our products
empower physicians around the world with a new generation of
analytical tools that deliver more meaningful information - using
sound and light as the guiding elements. Founded in cardiovascular
care and expanding into other specialties, Volcano is changing the
assumption about what is possible in improving patient outcomes by
combining imaging and therapy together.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered "forward-looking statements," including
statements regarding the potential benefits and effectiveness of
the products and technologies described above, further market
development and expansion and anticipated market impact.
Forward-looking statements are based on management's current
expectations and are subject to risks and uncertainties which may
cause Volcano's results to differ materially and adversely from the
statements contained herein. Some of the potential risks and
uncertainties that could cause actual results to differ include the
pace and extent of market adoption of the company's products and
technologies; unexpected clinical trial results, including
unexpected new clinical data and unexpected additional analysis of
existing clinical data; unexpected regulatory actions or delays or
government regulation generally; the company's ability to obtain or
maintain patent or other proprietary intellectual property
protection; competition in general; government, industry and
general public pricing pressures; unexpected manufacturing issues;
growth strategies; timing and achievement of product development
milestones; outcome of ongoing litigation; the impact and benefits
of market development; product introductions; unexpected new data,
safety and technical issues; market conditions; and other risks
inherent to medical device development and commercialization. These
and additional risks and uncertainties are more fully described in
Volcano's filings made with the Securities and Exchange Commission,
including our recent report on Form 10-K. Undue reliance should not
be placed on forward-looking statements which speak only as of the
date they are made. Volcano undertakes no obligation to update any
forward-looking statements to reflect new information, events or
circumstances after the date they are made, or to reflect the
occurrence of unanticipated events.